

Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice

SUPPLEMENTARY MATERIAL




Fig. S1: SHP2 inhibitor treatment blocks growth and survival of mouse mastocytoma cells. A. Graph depicts average colony numbers (mean \pm SD) for P815 cells treated with DMSO or indicated concentrations of II-B08 in methyl cellulose medium at day 8 (triplicate samples; * and ** indicates significant difference between treatments at $p < 0.05$ and $p < 0.01$, respectively). B. P815 cells were treated with DMSO or II-B08 (10, 20 or 50 μ M) for 72h. Graph depicts the percentage of viable cells based on alamar blue assay (** indicates significant difference between DMSO and II-B08 treated cells, $p < 0.01$). C. P815 cells were treated with either DMSO, Dasatinib (20 nM), or Dasatinib (20 nM) plus II-B08 (20 or 50 μ M) for 72hours. Graph depicts the percentage of viable cells based on alamar blue assay (** indicates significant difference between treatment groups, $p < 0.01$).